Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to treat a rare progressive lung disease for which there is no known cause or cure. The new drug has yet to be approved, but in small clinical trials has shown impressive efficacy in treating idiopathic pulmonary fibrosis (IPF).
Indeed, Musk suggested that synthetic data — data generated by AI models themselves — is the path forward. “The only way to supplement [real-world data] is with synthetic data, where the AI creates [training data],” he said. “With synthetic data … [AI] will sort of grade itself and go through this process of self-learning.”
Character.AI is facing scrutiny after reports revealed users created chatbots emulating real-life school shooters and their victims.
A study published today in the journal Nature by researchers at Columbia University described a new medical AI model that they say can accurately predict the activity of genes at the cellular level. In theory,
It was almost a year before a handful of Chinese AI chatbots received government approval for public release. Some questioned whether China’s stance on censorship might hobble the country’s AI ambitions.
What will shape AI governance? Industry leaders share key insights, highlighting diverse yet interconnected factors driving progress in ethics, regulation, and tech.
Generative AI projects will move from pilot phase to production for many companies this year, which means the workforce will be affected in ways never before imagined, says Sarah Hoffman, director of AI research at AlphaSense.
An AI expert argues AI progress hasn’t stalled, it’s become invisible, which could leave us unprepared for the future.
As more users turn to ChatGPT for emotional support, experts weigh its potential to reshape mental health care.
In 2021, researchers at MIT and McKinsey teamed up to ask more than 100 companies how they were using AI in their operations and to learn what separated the highest-performing companies from the rest.